Consolidated Statements of Income and Comprehensive (Loss) Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Revenues	$ 191,159	$ 164,456
Cost of products sold	145,138	122,142
Gross profit	46,021	42,314
Operating expenses:
Research and development	10,398	8,268
Selling, general and administrative	29,344	24,081
Intangible asset impairment	(12,181)	0
Total operating expenses	51,923	32,349
Operating (loss) income	(5,902)	9,965
Other expense (income):
Interest and financing expense	3,953	1,940
Miscellaneous income	(1,457)	(276)
Total other expense, net	2,496	1,664
(Loss) income before income taxes	(8,398)	8,301
Income tax (benefit) provision	(2,447)	1,892
Net (loss) income	(5,951)	6,409
Net (loss) income attributable to non-controlling interest	(53)	97
(Loss) income attributable to Ultralife Corporation	(5,898)	6,312
Other comprehensive income (loss):
Foreign currency translation adjustments	865	(346)
Comprehensive (loss) income attributable to Ultralife Corporation	$ (5,033)	$ 5,966
Net (loss) income per share attributable to Ultralife Corporation common stockholders – Basic (in dollars per share)	$ (35)	$ 38
Net (loss) income per share attributable to Ultralife Corporation common stockholders – Diluted (in dollars per share)	$ (35)	$ 38
Weighted average shares outstanding – Basic (in shares)	16,642	16,555
Weighted average shares outstanding – Diluted (in shares)	16,642	16,767